Table 5.
Variables that were found to be significant in one to 10 studies (n=55)
| Variables significant among the first five in two to 10 studies divided by the total studies in which the variable was tested (%) | Variables significant among the first five in only one study divided by the total studies in which the variable was tested (%) | Variables significant among the first five and tested in only one study | ||
|---|---|---|---|---|
| Untreated | 10/15 (67) | Viral load | 1/2 (50) | Centre of diagnosis |
| Tumour number | 8/22 (36) | ICG | 1/2 (50) | Modified JIS score |
| Albumin | 7/16 (44) | Creatinine | 1/3 (33) | Lymph nodes |
| Performance status | 6/8 (75) | JIS scale | 1/3 (33) | CRP |
| Age | 6/16 (38) | Period of surveillance | 1/3 (33) | α-1 antitrypsin |
| Treatment modality | 5/7 (71) | MELD | 1/5 (20) | Tumour echo |
| Metastases | 5/8 (63) | Hepatitis C | 1/6 (17) | Tumour margin |
| Ascites | 5/15 (33) | GGT | 1/7 (14) | SUV ratio |
| DCPa | 4/6 (67) | ALP | 1/10 (10) | Encapsulation |
| Gross HCCb | 4/9 (44) | LAK | ||
| Tumour stage | 4/14 (29) | TGF-β | ||
| Okuda scale | 4/15 (27) | NK | ||
| LCSGJ liver damage | 3/4 (75) | HBeAg | ||
| Tumour histology | 3/5 (60) | Tumour doubling time | ||
| Symptoms | 3/7 (43) | p53 | ||
| Alcohol | 2/2 (100) | IL-8 | ||
| Surgery | 2/2 (100) | HGF | ||
| LCSGJ stagec | 2/2 (100) | Combination of staging systems | ||
| AFP-L3 | 2/2 (100) | LINE-1 | ||
| BCLC scale | 2/3 (67) | |||
| Milan criteria | 2/3 (67) | |||
| Urea | 2/3 (67) | |||
| TACE | 2/3 (67) | |||
| Mode of detection | 2/6 (33) | |||
| Varices | 2/6 (33) | |||
| PT | 2/8 (25) | |||
| Hepatitis B | 2/10 (20) | |||
AFP-L3, lens-culinaris agglutinin-reactive fraction of α-foetoprotein; ALP, alkaline phosphatase; BCLC, Barcelona Clinic Liver Cancer; CRP, C reactive protein; DCP, des-gamma-carboxy prothrombin; GGT, ã-glutamyl transpeptidase; HBeAg, hepatitis B envelope antigen; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; ICG, indocyanine green clearance; IL, interleukin; JIS, Japanese Integrated System; LAK, lymphokine-activated killer activity; LCSGJ, Liver Cancer Study Group of Japan; MELD, model for end-stage liver disease; NK, natural killer activity; p53, anti-p53 antibody; PT, prothrombin time; SUV, standardized uptake value on positron emission tomography scan; TACE, transarterial chemoembolization; TGF-β, transforming growth factor-β.